Every day, millions of people fail to take their medications as prescribed and the resulting personal and financial costs are staggering. Worldwide, non-adherence results in $700 billion in avoidable medical costs.
The data we create is unique and has enormous value to pharmaceutical companies, researchers and governments.
Every time a patient uses our CuraServe technology, our data grows in utility and value.
Curaizon™ solves drug non-adherence problem by deploying our technology through national health services. As part of our solution, we collect fully anonymized data about how and when patients take medications.
CuraTokens™ are the only way to access our data. Tokens can be redeemed to access the data, which will advance medical research, drive down healthcare costs and save lives.
The value of a CuraToken™ is based on a real solution to a real problem.
CuraTokens™ are the only way to access Curaizon’s™ technology.
CuraToken™ holders can access data which utilizes powerful, predictive analytics, AI and big data in the fight against drug non-adherence.
CuraTokens™ provide real time analysis on patient behavior and adherence.
CuraTokens™ enable the use of blockchain technology to manage authentication, confidentiality and accountability by allowing individuals to be in control of their data, providing protection, security and compliance with all upcoming, required regulations, including GDPR.
CuraTokens™ facilitate partnerships with medical and pharmaceutical organizations through a token reward system.
CuraToken™ holders know they are saving lives around the world by helping to solve the problem of drug non-adherence.
Our team combines passion, innovation and expertise with experience in healthcare, finance, operations, marketing and technology
Chief Executive Officer (CEO)
Nicholas has a background in mathematics and economics and spent much of his working life inside investment banking. Most recently he was responsible for Saxo Bank’s Asia Pacific and Australasian operations. He was heavily engaged in both retail and institutional client relationships and was instrumental in pioneering new trading technologies. He brings more than 20 years of business experience and knows how to bring great teams of people together and execute high-level plans; especially where technology plays a key role.
Chief Operations Officer (COO)
Chris has an MBA in finance as well as a JD. He has experience as a financial analyst, director and executive as well as experience across startup and technology companies as well as an entrepreneur. In his roles at OrderTrust™ and CyberCash™ he developed high-volume payment related products deployed around the world. In his work as a consultant he has worked with a wide variety of companies around the world providing strategic analysis and fundraising support.
Chief Financial Officer (CFO)
Mark Nathan is a chartered accountant has been working with Curaizon since 2015. He has high-level experience in business operations across multiple sectors. His systems for comparing performance and costs against budget/forecast and extracting volume/mix variances in relation to the model's revenues to assess 'top-line' profitability has been deployed multiple times. Mark's focus has been to assist in the steady growth and development of the company, with a slant being on the control of costs across the business, through the annual budgeting process, and a quarterly re-forecasting program.
Chief Technology Officer (CTO)
Darran has delivered a range of IT solutions for clients ranging from blue chip companies to not for profits. He currently specializes in blockchain related projects providing technical expertise to address real world issues. Darran also has extensive experience in pioneering health sector redesign to meet the considerable demands of an aging population with multiple, complex health needs.
Chief Data Officer (CDO)
Luke has an extensive background in data modeling and systems. He has led complex data analysis projects with an emphasis on big data. His responsibilities include overseeing the data integration and data structure of CuraServe™ and CuraData™.
Andrey has designed more than 80 tokens and is widely considered a leading expert in token economics and crypto-currencies. He has consulted across a range of industries, advising on ICO’s and blockchain application strategies to drive business impact and bring value to investors, founders, and end users.
He brings enormous experience and expertise in technology, economics and behavioral science with over 20 years’ experience in telecommunications, product management and consulting, working with multiple Tier 1 clients across the globe.
Director of Business Development
Pencho has a background in Innovation and entrepreneurship. His experience as a marketing manager and business development consultant had positioned him well within the international business environment. A substantial amount of his work experience is within the healthcare sector where he has been successful in market acquisition activities by expanding sales across four continents. One of his top achievements is within strategic development where he successfully established co-branding partnership with Tracoe, world’s leading manufacturer of medical devices within the field of tracheotomy. Pencho has been working with Curaizon™ since it started in 2015.
Kristaps has a masters in both international business and innovation and entrepreneurship as well as advanced degrees in multimedia design & communication. He has work experience in global branding, marketing and communication strategy and execution, project management, multimedia development and human resources. His experience includes working at a leading global market research firm, industrial manufacturing, technology start-ups and his own creative agency. Kristaps creative mindset, coupled with his ability to work in diverse country and cultural environments, are a great asset for the team.
IoT, Cloud and security experts
Timengo are IoT, Cloud and security experts with a wealth of knowledge and experience within the healthcare sector. They drive our internal and external technology applications and help us to deliver secure API infrastructure with external databases.
MB BS, MSc, MRCGP
Rory has been described by the UK’s Financial Times as a “Health Entrepreneur”. He gained this reputation for his farsighted innovation as Chairman of ChilversMcCrea Healthcare, co-founding and overseeing, from startup in 2001 through to successful transfer in 2010 to a Trade Partner, a network of over 40 NHS General Practices and Urgent Care services across England and Wales. Rory has also been highly influential in the public sector having been a Medical Director with NHS West Essex for over a decade before becoming Director of Clinical Transformation with The West Essex Clinical Commissioning Group. Rory will be a driving force behind the adoption of Curaizon's™ technology across multiple national healthcare services. Rory has been an advisory board member of Curaizon's™ since 2015.
BSc, RGN, RHV, MBA, DProf
Sarah has spent her life working in, and with, the UK’s National Health Service. First as a registered nurse and a health visitor and then in NHS management. Sarah went on to complete her Professional Doctorate at The Middlesex University in 2004, specializing in new ways of delivering healthcare and has been working to drive innovation and clinical excellence for more than 25 years. Winner of the Laing and Buisson Independent Healthcare Award in 2008 for Entrepreneurial Achievement, Sarah has a perfect mix of clinical and business experience that has proven invaluable in her advisory role at Curaizon™ since 2015. She is responsible for integrating our clinical trials and the adoption of our technologies across multiple national health services.
Biopharmaceutical service provider
Parexel International is a global provider of biopharmaceutical services. It conducts clinical trials on behalf of its clients to expedite the approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. Parexel are our clinical trial partners in the UK and will deliver bridging studies for entry into each new territory.
CuraServe™ Development Begins
CuraServe™ Testing Underway
CuraData™ Alpha Release Complete
Token Presale Begins
Token Public Sale Begins
CuraData™ Beta Release Complete
CuraServe™ Public Release
CuraData™ Platform Growth
Curadata™ 2.0 Release
We aim to improve drug adherence and bring game-changing benefits to patients and healthcare providers by being the leading supplier of adherence and data solutions worldwide.
Our solution works with patients, their families and healthcare providers to ensure that patients take their medications as prescribed through a series of outreach tools, supported by predictive modeling tools and behavioural analysis, to increase the rate of drug adherence
Our CuraServe technology helps ensure that patients take their medicines as prescribed by their doctor. By doing this, we help patients live longer and healthier lives. We also reduce the healthcare costs that occur when patients fail to take their medications properly.
Our CuraServe™ technology generates a tremendous amount of unique, real-time data showing how people take their medications that is very valuable to a variety of groups including pharmaceutical companies, medical researchers and biotech companies. CuraTokens™ allow token owners access to the data to make queries. As our solution is rolled out to more and more patients in more and more countries. The more data we generate, the more valuable that CuraTokens™ become.
Curaizon™ sells its adherence (CuraServe™) solutions to national health services around the world. Our end users are the health service's patients who take any form of medication. We also work with academia, pharmaceutical and biotech industries, as well as other users of data via our CuraData™ solution.
Curaizon targets countries with national health services. This currently includes 1.4 Billion people and that number is growing.
The global cost of non-adherence is over €600 billion each year and results in hundreds of thousands of lives lost prematurely. Adherence for chronic and long-term illness is less than 50%.